Serum Levels of Soluble Fas in Patients with Graves' Ophthalmopathy

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 1999 Dec 28

PMID 10611108

Citations 6

Authors

K Ohtsuka

M Hashimoto

Affiliations

Soon will be listed here.

Abstract

Aim: To assess levels of soluble Fas (sFas) in the sera of patients with Graves' ophthalmopathy.

Methods: The subjects in this study were 43 patients with Graves' ophthalmopathy and 11 normal subjects. Serum levels of sFas were determined by sandwich enzyme linked immunosorbent assay. In addition, serum levels of thyroid stimulating antibody (TSAB) were also measured in all the patients.

Results: The mean serum level of sFas was 1.35 (SD 2.03) ng/ml in patients with Graves' ophthalmopathy, and 0.93 (0.32) ng/ml in normal subjects. Serum levels of sFas in the subgroup of 24 patients with diplopia (1.98 (2.56) ng/ml) were significantly higher than those in the subgroup of 19 patients without diplopia (0.56 (0.24) ng/ml) and normal subjects (p <0.001). Serum levels of sFas in the subgroup of 27 patients with extraocular muscle hypertrophy (1.81 (2. 46) ng/ml) were significantly higher than those in the subgroup of 16 patients without extraocular muscle hypertrophy (0.58 (0.26) ng/ml) among the patients with Graves' ophthalmopathy and normal subjects (p <0.001). Serum levels of sFas were not significantly different between the subgroup of 24 patients with proptosis (1.15 (0.98) ng/ml) and the subgroup of 19 patients without proptosis (1. 61 (2.88)). In contrast, the serum levels of TSAB in the subgroup of patients with proptosis (723% (1161%)) were significantly higher than those in the subgroup of patients without proptosis (194% (122%)) (p <0.05).

Conclusions: Elevated sFas levels were associated with extraocular muscle disorders but not with proptosis. On the other hand, elevated TSAB levels were associated with proptosis but not with extraocular muscle disorders, suggesting different immunological mechanisms for the extraocular muscle disorders and proptosis in Graves' ophthalmopathy. Determination of the serum levels of sFas and TSAB could provide useful markers for evaluation of the immunological processes involved in the development of Graves' ophthalmopathy.

Citing Articles

Increased Pretransplant Inflammatory Biomarkers Predict Death With Function After Kidney Transplantation.

Lorenz E, Smith B, Liang Y, Park W, Bentall A, Dhala A Transplantation. 2024; 108(12):2434-2445.

PMID: 38913783 PMC: 11666810. DOI: 10.1097/TP.0000000000005103.

Epidemiology of thyroid-stimulating immunoglobulin in recent-onset symptomatic thyroid eye disease.

Lai K, Aljufairi F, Sebastian J, Wei Y, Jia R, Chan K Eur Thyroid J. 2024; 13(4).

PMID: 38847819 PMC: 11301541. DOI: 10.1530/ETJ-23-0129.

Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.

Seo S, Sanchez Robledo M J Endocrinol Invest. 2018; 41(12):1457-1468.

PMID: 30194634 DOI: 10.1007/s40618-018-0945-6.

Outcome of thyroid associated ophthalmopathy treated by radiation therapy.

Abboud M, Arabi A, Salti I, Geara F Radiat Oncol. 2011; 6:46.

PMID: 21569461 PMC: 3108307. DOI: 10.1186/1748-717X-6-46.

Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.

Nabipour I, Kalantarhormozi M, Assadi M, Jafari S, Gharibi M, Ahmadi E Endocrine. 2010; 38(3):406-11.

PMID: 21042884 DOI: 10.1007/s12020-010-9401-x.

References

Kazuo K, Fujikado T, Ohmi G, Hosohata J, Tano Y . Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients. Br J Ophthalmol. 1998; 81(12):1080-3. PMC: 1722083. DOI: 10.1136/bjo.81.12.1080. View

Shimaoka Y, Hidaka Y, Okumura M, Takeoka K, Tada H, Amino N . Serum concentration of soluble Fas in patients with autoimmune thyroid diseases. Thyroid. 1998; 8(1):43-7. DOI: 10.1089/thy.1998.8.43. View

Bolonkin D, Tate R, Luber J, Kohn L, Winand R . Experimental exophthalmos. Binding of thyrotropin and an exophthalmogenic factor derived from thyrotropin to retro-orbital tissue plasma membranes. J Biol Chem. 1975; 250(16):6516-21. View

Rotella C, Zonefrati R, TOCCAFONDI R, Valente W, Kohn L . Ability of monoclonal antibodies to the thyrotropin receptor to increase collagen synthesis in human fibroblasts: an assay which appears to measure exophthalmogenic immunoglobulins in Graves' sera. J Clin Endocrinol Metab. 1986; 62(2):357-67. DOI: 10.1210/jcem-62-2-357. View

Tallstedt L, NORBERG R . Immunohistochemical staining of normal and Graves' extraocular muscle. Invest Ophthalmol Vis Sci. 1988; 29(2):175-84. View

Morris 3rd J, Hay I, Nelson R, JIANG N . Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. Mayo Clin Proc. 1988; 63(7):707-17. DOI: 10.1016/s0025-6196(12)65533-5. View

Weetman A, Cohen S, Gatter K, Fells P, Shine B . Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol. 1989; 75(2):222-7. PMC: 1542121. View

Bahn R, Heufelder A . Retroocular fibroblasts: important effector cells in Graves' ophthalmopathy. Thyroid. 1992; 2(1):89-94. DOI: 10.1089/thy.1992.2.89. View

Heufelder A, Bahn R . Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy. Eur J Clin Invest. 1993; 23(1):10-7. DOI: 10.1111/j.1365-2362.1993.tb00712.x. View

10.

Heufelder A, Bahn R . Modulation of Graves' orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists. Invest Ophthalmol Vis Sci. 1994; 35(1):120-7. View

11.

Cheng J, Zhou T, Liu C, Shapiro J, BRAUER M, Kiefer M . Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263(5154):1759-62. DOI: 10.1126/science.7510905. View

12.

Bartley G . The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994; 92:477-588. PMC: 1298522. View

13.

Ludgate M, Vassart G . The thyrotropin receptor as a model to illustrate receptor and receptor antibody diseases. Baillieres Clin Endocrinol Metab. 1995; 9(1):95-113. DOI: 10.1016/s0950-351x(95)80851-5. View

14.

Drappa J, Vaishnaw A, Sullivan K, Chu J, Elkon K . Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996; 335(22):1643-9. DOI: 10.1056/NEJM199611283352204. View

15.

Inoue A, Koh C, Sakai T, Yamazaki M, Yanagisawa N, Usuku K . Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J Neuroimmunol. 1997; 75(1-2):141-6. DOI: 10.1016/s0165-5728(97)00012-x. View

16.

Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H . Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum. 1997; 40(6):1126-9. DOI: 10.1002/art.1780400617. View

17.

Bijl M, van Lopik T, Limburg P, Spronk P, Jaegers S, Aarden L . Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?. J Autoimmun. 1998; 11(5):457-63. DOI: 10.1006/jaut.1998.0233. View